- Home
- OTLK vs MX Comparison
OTLK vs MX Comparison
Compare OTLK & MX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLK | MX |
|---|---|---|
| Founded | 2010 | 2003 |
| Country | United States | South Korea |
| Employees | 17 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.3M | 95.0M |
| IPO Year | 2016 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLK | MX |
|---|---|---|
| Price | $0.56 | $2.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $4.50 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 8.1M | 292.2K |
| Earning Date | 02-13-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $1,413,535.00 | ★ $224,755,000.00 |
| Revenue This Year | $2,048.59 | N/A |
| Revenue Next Year | $142.11 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 14.62 |
| 52 Week Low | $0.60 | $2.18 |
| 52 Week High | $3.39 | $5.16 |
Technical Indicators
Market Signals| Indicator | OTLK | MX |
|---|---|---|
| Relative Strength Index (RSI) | 22.80 | 56.65 |
| Support Level | $1.78 | $2.53 |
| Resistance Level | $2.03 | $2.81 |
| Average True Range (ATR) | 0.25 | 0.10 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 2.64 | 94.50 |
Price Performance
Historical ComparisonAbout OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About MX Magnachip Semiconductor Corporation
MagnaChip Semiconductor Corp designs and manufactures analog and mixed-signal semiconductor platform solutions for communications, Internet of Things applications, consumer, industrial and automotive applications. The company's product portfolio consists of large display solutions, mobile display solutions, sensor solutions, LED solutions, mobile solutions, and power conversions. The company operates in two segments namely, Transitional Fab 3 foundry services and Standard products business. The company operates in Korea, Asia Pacific (other than Korea), United States and Europe.